Literature DB >> 18317865

Triptans in the Italian population: a drug utilization study and a literature review.

Alessandro Panconesi, Eleonora Pavone, Franca Vacca, Monica Vaiani, Roberto Banfi.   

Abstract

Previous studies performed in selected populations show a poor utilization of triptans for migraine. The objectives of our study were to establish patterns of triptans utilization in a large sample, covering 1/10 of Italian population (5.57 millions), and to perform a review of published studies on this topic. We investigated drug prescription database collected during 2006 from 33 health authorities distributed in 8 different regions. About 0.6% of the subjects received at least one prescription of triptans in 1 year: 77.7% were females and 22.3% males. Age distribution shows that 9.5% of patients were aged above 65, and received prescriptions for 8.2% of packages. The review of the literature suggests that these percentages of utilization are common to several countries, and shows that occasional triptan users who received only one prescription in 1 year are a large percentage (40-60%); moreover, a minor population of triptan users utilize a large amount of total triptans. Finally triptans are frequently prescribed in people aged above 65 years, a population in which triptans are contraindicated or not recommended. Our study and the analyzed ones indicate suboptimal treatment of migraine patients with triptans and also an incorrect use in some patients (triptan abusers, elderly).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18317865      PMCID: PMC3476185          DOI: 10.1007/s10194-008-0020-3

Source DB:  PubMed          Journal:  J Headache Pain        ISSN: 1129-2369            Impact factor:   7.277


  29 in total

1.  The International Classification of Headache Disorders: 2nd edition.

Authors: 
Journal:  Cephalalgia       Date:  2004       Impact factor: 6.292

2.  Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials.

Authors:  M D Ferrari; K I Roon; R B Lipton; P J Goadsby
Journal:  Lancet       Date:  2001-11-17       Impact factor: 79.321

3.  Features of medication overuse headache following overuse of different acute headache drugs.

Authors:  V Limmroth; Z Katsarava; G Fritsche; S Przywara; H-C Diener
Journal:  Neurology       Date:  2002-10-08       Impact factor: 9.910

4.  Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation survey.

Authors:  E Anne MacGregor; Jan Brandes; Astrid Eikermann
Journal:  Headache       Date:  2003-01       Impact factor: 5.887

5.  Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients.

Authors:  Stewart Tepper; Christopher Allen; David Sanders; Alison Greene; Stephen Boccuzzi
Journal:  Headache       Date:  2003-01       Impact factor: 5.887

6.  Use and misuse of triptans in France: data from the GRIM2000 population survey.

Authors:  C Lucas; J-P Auray; A-F Gaudin; J-F Dartigues; G Duru; P Henry; M Lantéri-Minet; A Pradalier; G Chazot; A El Hasnaoui
Journal:  Cephalalgia       Date:  2004-03       Impact factor: 6.292

7.  Single use of sumatriptan: a patient interview study.

Authors:  H Rahimtoola; H Buurma; C C Tijssen; H G Leufkens; A C G Egberts
Journal:  Headache       Date:  2003-02       Impact factor: 5.887

8.  Headache treatment before and after the consultation of a specialized centre: a pharmacoepidemiology study.

Authors:  A Ferrari; G Pasciullo; G Savino; A F G Cicero; A Ottani; A Bertolini; E Sternieri
Journal:  Cephalalgia       Date:  2004-05       Impact factor: 6.292

9.  Patterns of triptans use: a study based on the records of a community pharmaceutical department.

Authors:  E Pavone; R Banfi; M Vaiani; A Panconesi
Journal:  Cephalalgia       Date:  2007-08-06       Impact factor: 6.292

10.  Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray.

Authors:  Lauren Hoffman; George Mayzell; Alex Pedan; Maureen Farrell; Thomas Gilbert
Journal:  J Manag Care Pharm       Date:  2003 Jul-Aug
View more
  7 in total

1.  Pattern of triptan use and cardiovascular coprescription: a pharmacoepidemiological study in Italy.

Authors:  Chiara Biagi; Elisabetta Poluzzi; Giuseppe Roberto; Aurora Puccini; Alberto Vaccheri; Roberto D'Alessandro; Domenico Motola; Nicola Montanaro
Journal:  Eur J Clin Pharmacol       Date:  2011-06-15       Impact factor: 2.953

2.  Treatment of migraine and tension-type headache in Croatia.

Authors:  Vlasta Vuković; Davor Plavec; Arijana Lovrencić Huzjan; Mislav Budisić; Vida Demarin
Journal:  J Headache Pain       Date:  2010-03-06       Impact factor: 7.277

3.  Triptan use among hospital workers affected by migraine.

Authors:  G Viticchi; L Falsetti; L Buratti; A Plutino; L Provinciali; M Silvestrini; M Bartolini
Journal:  Neurol Sci       Date:  2015-05       Impact factor: 3.307

4.  Long-term effects of a sensitisation campaign on migraine: the Casilino study.

Authors:  B Petolicchio; L Di Clemente; M Altieri; E Vicenzini; G L Lenzi; Vittorio Di Piero
Journal:  J Headache Pain       Date:  2010-04       Impact factor: 7.277

Review 5.  Migraine pain: reflections against vasodilatation.

Authors:  Alessandro Panconesi; Maria Letizia Bartolozzi; Leonello Guidi
Journal:  J Headache Pain       Date:  2009-06-05       Impact factor: 7.277

6.  Treatment adherence among new triptan users: a 2-year cohort study in Taiwan.

Authors:  Ting-Bin Chen; Yung-Tai Chen; Jong-Ling Fuh; Chao-Hsiun Tang; Shuu-Jiun Wang
Journal:  J Headache Pain       Date:  2014-08-12       Impact factor: 7.277

7.  Analgesic Medicine Utilization in Older People in New Zealand from 2005 to 2013.

Authors:  Prasad S Nishtala; Sekbong Oh; Daniel Kim; Natalie Chun; Siti Fatimah Binti Kamis; Kuan-Cia Kiu
Journal:  Drugs Real World Outcomes       Date:  2015-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.